Cargando…

Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study

AIM AND OBJECTIVE: To evaluate the therapeutic efficacy of oral pentoxifylline in the treatment of oral submucous fibrosis (OSMF) patients by assessing the clinical symptoms such as burning sensation, mouth opening, and submucosal layer thickness and echogenicity using ultrasonography, both pre- and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadaksharam, Jayachandran, Mahalingam, Sureshkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551322/
https://www.ncbi.nlm.nih.gov/pubmed/28839403
http://dx.doi.org/10.4103/ccd.ccd_1192_16
_version_ 1783256293620842496
author Sadaksharam, Jayachandran
Mahalingam, Sureshkumar
author_facet Sadaksharam, Jayachandran
Mahalingam, Sureshkumar
author_sort Sadaksharam, Jayachandran
collection PubMed
description AIM AND OBJECTIVE: To evaluate the therapeutic efficacy of oral pentoxifylline in the treatment of oral submucous fibrosis (OSMF) patients by assessing the clinical symptoms such as burning sensation, mouth opening, and submucosal layer thickness and echogenicity using ultrasonography, both pre- and post-operatively. MATERIALS AND METHODS: Thirty study subjects were included in the study and divided into two groups in single-blind randomized manner, oral pentoxifylline and dexamethasone group. Burning sensation, mouth opening, ultrasonographic submucosal thickness, and echogenicity were recorded both pre- and post-operatively. Any adverse effects reported by the patients were also noted. The data collected were statistically analyzed, and response to pentoxifylline and intralesional dexamethasone with hyaluronidase was observed using ultrasonography. RESULTS: A highly significant reduction (P < 0.001) in burning sensation, improvement in mouth opening, and changes in submucosal thickness were noticed in both groups, and significant improvement (P < 0.05) in echogenicity in both the groups was noticed. However, pentoxifylline group showed marginally better improvement than dexamethasone group. CONCLUSION: Pentoxifylline can bring about significant improvement in OSMF, which can be used as better alternative where intralesional steroid was contraindicated or not well tolerated.
format Online
Article
Text
id pubmed-5551322
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55513222017-08-24 Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study Sadaksharam, Jayachandran Mahalingam, Sureshkumar Contemp Clin Dent Original Article AIM AND OBJECTIVE: To evaluate the therapeutic efficacy of oral pentoxifylline in the treatment of oral submucous fibrosis (OSMF) patients by assessing the clinical symptoms such as burning sensation, mouth opening, and submucosal layer thickness and echogenicity using ultrasonography, both pre- and post-operatively. MATERIALS AND METHODS: Thirty study subjects were included in the study and divided into two groups in single-blind randomized manner, oral pentoxifylline and dexamethasone group. Burning sensation, mouth opening, ultrasonographic submucosal thickness, and echogenicity were recorded both pre- and post-operatively. Any adverse effects reported by the patients were also noted. The data collected were statistically analyzed, and response to pentoxifylline and intralesional dexamethasone with hyaluronidase was observed using ultrasonography. RESULTS: A highly significant reduction (P < 0.001) in burning sensation, improvement in mouth opening, and changes in submucosal thickness were noticed in both groups, and significant improvement (P < 0.05) in echogenicity in both the groups was noticed. However, pentoxifylline group showed marginally better improvement than dexamethasone group. CONCLUSION: Pentoxifylline can bring about significant improvement in OSMF, which can be used as better alternative where intralesional steroid was contraindicated or not well tolerated. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5551322/ /pubmed/28839403 http://dx.doi.org/10.4103/ccd.ccd_1192_16 Text en Copyright: © 2017 Contemporary Clinical Dentistry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sadaksharam, Jayachandran
Mahalingam, Sureshkumar
Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title_full Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title_fullStr Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title_full_unstemmed Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title_short Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis – An Ultrasonographic Study
title_sort evaluation of oral pentoxifylline in the management of oral submucous fibrosis – an ultrasonographic study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551322/
https://www.ncbi.nlm.nih.gov/pubmed/28839403
http://dx.doi.org/10.4103/ccd.ccd_1192_16
work_keys_str_mv AT sadaksharamjayachandran evaluationoforalpentoxifyllineinthemanagementoforalsubmucousfibrosisanultrasonographicstudy
AT mahalingamsureshkumar evaluationoforalpentoxifyllineinthemanagementoforalsubmucousfibrosisanultrasonographicstudy